Takeda Submits a New Drug Application for Vedolizumab for the Treatment of Moderately to Severely Ulcerative Colitis in Japan

Osaka, Japan, August 22, 2017 - Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announced today that it has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for the investigational humanized monoclonal antibody vedolizumab (generic name, development code: MLN0002) for the treatment of adults with moderately to severely active ulcerative colitis (UC).

The NDA filing included data from Study CCT-101, a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study investigating the efficacy, safety and pharmacokinetics of vedolizumab induction and maintenance treatment involving 292 Japanese patients with moderate or severe UC. Results from Study CCT-101 will be presented at scientific meeting in the future¹. The NDA filing also included data from the international, randomized, double blind, placebo-controlled GEMINI I pivotal Phase 3 study of vedolizumab induction and maintenance treatment involving 895 patients with moderate to severe UC.²

“UC is a chronic, progressive inflammatory disease of the large intestine, which typically affects young adults. The disease has a high impact on their quality of life with symptoms including diarrhea, rectal bleeding, incontinence and abdominal pain,” said Toshiro Heya, head of Takeda Development Center Japan. “Through this submission, we may provide an alternative treatment option to the increasing number of people with UC in Japan.”

“We aim to provide life changing therapeutics for individuals suffering from GI diseases by focusing on underlying disease drivers and leveraging diverse modalities,” said Dr. Asit Parikh, head of Gastroenterology Therapeutic Area.

 

Vedolizumab was approved in the European Union and the U.S. in May 2014 for the treatment of adults with moderately to severely active UC or Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist. Currently, vedolizumab is approved in more than 60 countries with over 113,000 patient years of exposure to date.³

About ulcerative colitis
Ulcerative colitis is one of the most common forms of inflammatory bowel disease (IBD),^3,4 with over 160,000 people with UC in Japan.⁴ UC is a chronic, relapsing, remitting, inflammatory condition of the gastrointestinal (GI) tract that is often progressive in nature.⁵ UC involves the innermost lining of the large intestine and often presents with symptoms of abdominal discomfort, loose bowel movements, including blood or pus.^6,7 The cause of UC is not fully understood, however recent research suggests hereditary, genetics, environmental factors and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to UC.^8,9

About vedolizumab
Vedolizumab is a prescription medicine approved for adults with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) in more than 60 countries worldwide.^10,11 In people with UC, there’s an increased number of inflammatory white blood cells entering the mucosal lining of the bowel.¹² The presence of these inflammatory cells can lead to the symptoms most commonly seen in people who have UC.^13,14,15 Vedolizumab is designed to reduce this inflammation by blocking the movement of the white blood cells into the inflamed gut tissue. Mucosal addressin cell adhesion molecule 1 (MAdCAM-1) is preferentially expressed on the endothelial lining of blood vessels in the lymphoid tissue of the bowel.¹⁶ The alpha4beta7 integrin is expressed on a subset of circulating white blood cells. Vedolizumab specifically binds to the alpha4beta7 integrin and blocks its interaction with MAdCAM-1, therefore inhibiting the white blood cells from entering the inflamed gut tissue, thus decreasing inflammation.¹⁴

About the GEMINI Studies
The safety and efficacy of vedolizumab is supported by the results of the GEMINI clinical trial program. These Phase 3 studies involved 2,400 individuals with ulcerative colitis (UC) or Crohn’s disease (CD) who were recruited from nearly 40 countries.^17,18,19,20

The GEMINI program consists of four studies – a placebo-controlled study of vedolizumab induction and maintenance treatment in patients with moderately to severely active UC (GEMINI I), a placebo-controlled study of vedolizumab induction and maintenance treatment in patients with moderately to severely active CD (GEMINI II), a placebo-controlled study of vedolizumab induction in patients with moderately to severely active CD (GEMINI III) and an open-label long-term safety study of vedolizumab in patients with either CD or UC (GEMINI long-term safety).^19,20,21

Takeda’s Commitment to Gastroenterology
More than 70 million people worldwide are impacted by gastrointestinal (GI) diseases, which can be complex, debilitating and life-changing.²¹ Takeda is driven to improving the lives of patients with GI diseases through innovative medicines, dedicated patient disease management support and the evolution of the healthcare environment. Takeda is leading in gastroenterology through the delivery of innovative medicines in areas associated with high unmet needs, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI research & development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies. With more than 25 years of experience in this area, our broad approach to treating many diseases that impact the GI system and our global network of collaborators, Takeda aims to advance how patients manage their disease.

###

Disclaimer

The drug information contained herein is intended to disclose Takeda's corporate information. Nothing contained herein should be considered a solicitation, promotion or indication for any prescription drug including the ones under development.

---

Media Contacts
Takeda Pharmaceutical Company Limited

CCPA Corporate Communications
Kazumi Kobayashi
Tel: +81-3-3278-2095
[email protected]

For media outside Japan
Luke Willats
Tel: +41-44-555-1145
[email protected]